Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$310K Sell
2,395
-6,732
-74% -$815K 0.01% 45
2025
Q1
$1.09M Sell
9,127
-1,993
-18% -$247K 0.04% 44
2024
Q4
$1.29M Buy
11,120
+3,927
+55% +$496K 0.05% 41
2024
Q3
$987K Buy
7,193
+1,107
+18% +$148K 0.04% 39
2024
Q2
$825K Sell
6,086
-2,883
-32% -$392K 0.03% 40
2024
Q1
$1.16M Sell
8,969
-1,126
-11% -$136K 0.04% 37
2023
Q4
$1.15M Buy
10,095
+3,765
+59% +$376K 0.04% 38
2023
Q3
$576K Buy
6,330
+950
+18% +$98K 0.02% 39
2023
Q2
$606K Buy
+5,380
New +$569K 0.02% 37

Other funds holding XYL

Martin Currie's XYL Position: Q2 2025 in Review

Martin Currie reduced its Xylem (XYL) stake by 74% in Q2 2025, selling an estimated $815K and leaving 2,395 shares worth $310K. The position accounts for 0.01% of the portfolio, ranked #45.

Martin Currie first reported a position in XYL in Q2 2023 and has held it in 9 quarters since. The position peaked at $1.29M in Q4 2024. 1,064 funds tracked by Wall St. Rank hold XYL as of Q2 2025.

  • Martin Currie held 2,395 shares of Xylem worth $310K as of Q2 2025.
  • Martin Currie sold 6,732 Xylem shares in Q2 2025, an estimated $815K.
  • Xylem made up 0.01% of Martin Currie's portfolio in Q2 2025, its #45 holding.
  • Martin Currie first reported a position in Xylem in Q2 2023 and has held it in 9 quarters since.
  • Martin Currie's Xylem position peaked at $1.29M in Q4 2024.
  • 1,064 funds tracked by Wall St. Rank held Xylem as of Q2 2025.

Based on Martin Currie's 13F filing for Q2 2025, filed 12 Aug 2025.